| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $41,802 | 4 | 100 |
| TAHL CINDY | See Remarks | 0 | $0 | 2 | $20,848 | $-20,848 |
| Valamehr Bahram | President and CEO | 0 | $0 | 2 | $20,954 | $-20,954 |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Fate Therapeutics, Inc. have bought $0 and sold $41,802 worth of Fate Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Fate Therapeutics, Inc. have bought $1.13M and sold $13.72M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 397,964 shares for transaction amount of $668,580 was made by Redmile Group, LLC () on 2024‑12‑20.
| 2026-01-09 | Sale | TAHL CINDY | See Remarks | 10,589 0.0093% | $1.06 | $11,275 | +1.90% | |
| 2026-01-09 | Sale | Valamehr Bahram | President and CEO | 5,190 0.0046% | $1.07 | $5,557 | +1.90% | |
| 2025-08-04 | Sale | TAHL CINDY | See Remarks | 9,037 0.0078% | $1.06 | $9,573 | +0.94% | |
| 2025-08-04 | Sale | Valamehr Bahram | President and CEO | 14,466 0.0126% | $1.06 | $15,396 | +0.94% | |
| 2025-01-10 | Sale | Valamehr Bahram | President and CEO | 8,705 0.008% | $1.54 | $13,406 | -23.81% | |
| 2025-01-10 | Sale | TAHL CINDY | See Remarks | 5,654 0.0052% | $1.55 | $8,764 | -23.81% | |
| 2025-01-10 | Sale | Bressi Jerome Charles | See Remarks | 5,980 0.0055% | $1.55 | $9,269 | -23.81% | |
| 2024-12-20 | Sale | Redmile Group, LLC | 341,633 0.2991% | $1.68 | $573,943 | -32.14% | ||
| 2024-12-20 | Redmile Group, LLC | 397,964 0.3484% | $1.68 | $668,580 | -32.14% | |||
| 2024-08-06 | Sale | Xu Yuan | director | 633 0.0005% | $4.23 | $2,678 | -68.30% | |
| 2024-03-04 | Sale | Dulac Edward J III | Chief Financial Officer | 2,447 0.0027% | $7.77 | $19,013 | -51.55% | |
| 2024-01-29 | Sale | Dulac Edward J III | Chief Financial Officer | 1,849 0.0017% | $5.00 | $9,245 | -36.19% | |
| 2024-01-09 | Sale | Wolchko J Scott | President and CEO | 14,391 0.0145% | $4.37 | $62,889 | -14.74% | |
| 2024-01-09 | Sale | Valamehr Bahram | Chief R&D Officer | 11,271 0.0114% | $4.38 | $49,367 | -14.74% | |
| 2024-01-09 | Sale | TAHL CINDY | General Counsel and Secretary | 10,874 0.0109% | $4.37 | $47,519 | -14.74% | |
| 2024-01-09 | Sale | Dulac Edward J III | Chief Financial Officer | 7,028 0.0071% | $4.37 | $30,712 | -14.74% | |
| 2024-01-02 | Sale | Dulac Edward J III | Chief Financial Officer | 5,182 0.0052% | $3.66 | $18,966 | +2.57% | |
| 2023-12-26 | Redmile Group, LLC | 44,630 0.0455% | $3.72 | $166,024 | +2.15% | |||
| 2023-12-18 | Sale | Dulac Edward J III | Chief Financial Officer | 1,585 0.0018% | $3.50 | $5,548 | +20.63% | |
| 2023-11-09 | Sale | TAHL CINDY | General Counsel and Secretary | 24,363 0.0278% | $2.40 | $58,471 | +78.40% |
| TAHL CINDY | See Remarks | 387081 0.3356% | $460,626.39 | 0 | 28 | |
| Valamehr Bahram | President and CEO | 329708 0.2858% | $392,352.52 | 0 | 20 | |
| Redmile Group, LLC | 12884277 11.1695% | $15.33M | 9 | 2 | +6.55% | |
| NELSEN ROBERT | 2473188 2.144% | $2.94M | 1 | 0 | <0.0001% | |
| ARCH VENTURE FUND VI LP | 10 percent owner | 2473188 2.144% | $2.94M | 1 | 0 | <0.0001% |
| VENROCK ASSOCIATES V LP | 10 percent owner | 2473187 2.144% | $2.94M | 1 | 0 | <0.0001% |
| Polaris Venture Management Co. V, L.L.C. | 10 percent owner | 2473186 2.144% | $2.94M | 1 | 0 | <0.0001% |
| RASTETTER WILLIAM H | director | 459272 0.3981% | $546,533.68 | 2 | 0 | +1.02% |
| Wolchko J Scott | President and CEO | 371248 0.3218% | $441,785.12 | 0 | 37 | |
| MENDLEIN JOHN | director | 282770 0.2451% | $336,496.30 | 3 | 2 | <0.0001% |
| Bressi Jerome Charles | See Remarks | 270203 0.2342% | $321,541.57 | 0 | 1 | |
| Chu Yu-Waye | Chief Medical Officer | 140676 0.122% | $167,404.44 | 0 | 6 | |
| Plavsic Mark | Chief Technical Officer | 123705 0.1072% | $147,208.95 | 0 | 2 | |
| Dulac Edward J III | Chief Financial Officer | 101479 0.088% | $120,760.01 | 0 | 13 | |
| Shoemaker Daniel D | Chief Scientific Officer | 73020 0.0633% | $86,893.80 | 0 | 13 | |
| COUGHLIN TIMOTHY | 57632 0.05% | $68,582.08 | 1 | 1 | +11.55% | |
| Powl Brian T. | Chief Commercial Officer | 41146 0.0357% | $48,963.74 | 0 | 1 | |
| Storgard Chris | Chief Medical Officer | 37593 0.0326% | $44,735.67 | 1 | 0 | +11.55% |
| Xu Yuan | director | 8669 0.0075% | $10,316.11 | 0 | 3 | |
| Nashat Amir | director | 7539 0.0065% | $8,971.41 | 1 | 20 | <0.0001% |
| Flynn Peter D | See remarks | 4039 0.0035% | $4,806.41 | 0 | 8 | |
| HERSHBERG ROBERT | 2009 0.0017% | $2,390.71 | 0 | 1 | ||
| Agarwal Shefali | 1840 0.0016% | $2,189.60 | 0 | 2 | ||
| Jooss Karin | 1198 0.001% | $1,425.62 | 0 | 1 | ||
| Weyer Christian | See remarks | 0 0% | $0 | 0 | 2 |
$17,525,882 | 60 | 5.22% | $115.46M | |
$48,218,096 | 42 | 0.89% | $135.07M | |
$6,578,958 | 42 | 10.77% | $150.84M | |
$7,147,964 | 34 | 24.78% | $146.64M | |
$1,323,997 | 34 | 0.21% | $157.79M | |
$47,292,212 | 27 | -28.21% | $158.53M | |
Fate Therapeutics, Inc. (FATE) | $295,092,700 | 21 | -0.27% | $137.27M |
$111,692,551 | 18 | 13.51% | $120.82M | |
$448,999,793 | 15 | -19.99% | $144.9M | |
$178,593,887 | 15 | -14.86% | $145.86M | |
$245,302 | 15 | -4.08% | $132.31M | |
$4,701,608 | 14 | -4.34% | $164.06M | |
$15,799,576 | 12 | -39.52% | $127.09M | |
$2,762,881 | 8 | -10.76% | $118.93M | |
$22,090,972 | 7 | -3.49% | $135.78M | |
$299,343 | 6 | -44.75% | $136.46M | |
$556,839 | 5 | 13.42% | $159.44M | |
$20,729,984 | 5 | 51.71% | $117.74M | |
$19,175,155 | 2 | 40.00% | $144.38M |
| Increased Positions | 68 | +45.95% | 15M | +18.87% |
| Decreased Positions | 55 | -37.16% | 14M | -17.43% |
| New Positions | 25 | New | 10M | New |
| Sold Out Positions | 16 | Sold Out | 3M | Sold Out |
| Total Postitions | 161 | +8.78% | 81M | +1.43% |
| Redmile Group, Llc | $12,693.00 | 11.19% | 12.87M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $10,531.00 | 9.29% | 10.68M | -129,754 | -1.2% | 2025-09-30 |
| Vanguard Group Inc | $8,675.00 | 7.65% | 8.8M | +31,727 | +0.36% | 2025-09-30 |
| Wilshire Advisors Llc | $8,368.00 | 7.38% | 8.49M | +8M | New | 2025-09-30 |
| Johnson & Johnson | $3,332.00 | 2.94% | 3.38M | 0 | 0% | 2025-09-30 |
| Acadian Asset Management Llc | $2,672.00 | 2.36% | 2.71M | +250,280 | +10.17% | 2025-09-30 |
| Geode Capital Management, Llc | $2,495.00 | 2.2% | 2.53M | +101,045 | +4.16% | 2025-09-30 |
| Vestal Point Capital, Lp | $2,480.00 | 2.19% | 2.52M | 0 | 0% | 2025-09-30 |
| State Street Corp | $2,383.00 | 2.1% | 2.42M | +188,014 | +8.43% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $2,066.00 | 1.82% | 2.09M | -342,754 | -14.06% | 2025-09-30 |